Central Hospital, Nancy, France — Biomedical Watch V2

Traitements6programmes

Essais3liés

Publications13liées

SourceDBlocale

Traitements

6

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System)The purpose is to determine the hypercoagulable phenotype by thrombinography associated to an increased risk of symptomatic and objectively confirmed first venous thrombotic event. This is a case-control study in a population with patients having systemic lupus erythematosus (SLE) and/or antiphospholipid antibodies (APL). Secondary purposes are: 1. To determine the frequency of hypercoagulable phenotype in study population; 2. To analyze the sensibility: consequences of variation of hypercoagulable phenotype threshold on the importance of risk; 3. To identify (genetic and not) factors for hypercoagulable phenotype and their frequency in different groups.	Lupus	NA	Traitement symptomatique		À vérifier
PLASM-ALZ — Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers.The goal of this interventional study is to estimate the diagnostic performance of plasma biomarkers of interest (Aβ40 and Aβ42, P-Tau and NFL), enabling discrimination between patients with and without a pathophysiological AD process. The main questions it aims to answer are: * to define a threshold value for each of the plasma, * to describe the correlations between the plasma biomarkers of interest and the other biological analyses performed as part of care, in particular triglyceridemia, cholesterolemia, glycemia and proteinemia, * to describe biomarker results in relation to comorbidities, in particular dyslipidemia and diabetes * to describe the final diagnosis and results obtained for plasma biomarkers, for patients with intermediate results according to the A/T/N classification (A-/T+ or A+/T-) Participants will be selected among patients undergoing lumbar puncture for the differential diagnosis of AD at Nancy University Hospital.	Alzheimer	NA	À vérifier	France	À vérifier
retrospective analysis of a panel resultABSTRACT Background and Aims: To determine the diagnostic performance of the epilepsy and intellectual disability panel used in the pediatric population, starting in June 2019, at the Regional University Hospital Center of Nancy, France. Design: An observational and retrospective study, at the Regional University Hospital Center of Nancy, France. Materials and Methods: Pediatric patients who underwent genetic analysis with the epilepsy-intellectual disability gene panel. All of these patients were either epileptic or had intellectual disability, or both, of undetermined etiology. Results: We included 69 patients in this study. We identified causative mutations in 46.4% (32 of 69 patients) of this cohort after the gene panel and 52.2% (36 patients) including positive results after realization of the Clinical Exome Solution.	Épilepsie	À vérifier	À vérifier	France	À vérifier
Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System)The purpose is to determine the hypercoagulable phenotype by thrombinography associated to an increased risk of symptomatic and objectively confirmed first venous thrombotic event. This is a case-control study in a population with patients having systemic lupus erythematosus (SLE) and/or antiphospholipid antibodies (APL). Secondary purposes are: 1. To determine the frequency of hypercoagulable phenotype in study population; 2. To analyze the sensibility: consequences of variation of hypercoagulable phenotype threshold on the importance of risk; 3. To identify (genetic and not) factors for hypercoagulable phenotype and their frequency in different groups.	Lupus	NA	Traitement symptomatique		À vérifier
retrospective analysis of a panel resultABSTRACT Background and Aims: To determine the diagnostic performance of the epilepsy and intellectual disability panel used in the pediatric population, starting in June 2019, at the Regional University Hospital Center of Nancy, France. Design: An observational and retrospective study, at the Regional University Hospital Center of Nancy, France. Materials and Methods: Pediatric patients who underwent genetic analysis with the epilepsy-intellectual disability gene panel. All of these patients were either epileptic or had intellectual disability, or both, of undetermined etiology. Results: We included 69 patients in this study. We identified causative mutations in 46.4% (32 of 69 patients) of this cohort after the gene panel and 52.2% (36 patients) including positive results after realization of the Clinical Exome Solution.	Épilepsie	À vérifier	À vérifier	France	À vérifier
PLASM-ALZ — Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers.The goal of this interventional study is to estimate the diagnostic performance of plasma biomarkers of interest (Aβ40 and Aβ42, P-Tau and NFL), enabling discrimination between patients with and without a pathophysiological AD process. The main questions it aims to answer are: * to define a threshold value for each of the plasma, * to describe the correlations between the plasma biomarkers of interest and the other biological analyses performed as part of care, in particular triglyceridemia, cholesterolemia, glycemia and proteinemia, * to describe biomarker results in relation to comorbidities, in particular dyslipidemia and diabetes * to describe the final diagnosis and results obtained for plasma biomarkers, for patients with intermediate results according to the A/T/N classification (A-/T+ or A+/T-) Participants will be selected among patients undergoing lumbar puncture for the differential diagnosis of AD at Nancy University Hospital.	Alzheimer	NA	À vérifier	France	À vérifier

Essais cliniques

3

Molécule	Indication / population	Phase	NCT	Titre	Statut
PLASM-ALZ — Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers	Alzheimer	NA	NCT06304129	PLASM-ALZ — Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers	NOT_YET_RECRUITING
retrospective analysis of a panel result	Épilepsie	À vérifier	NCT05193890	Using Next-generation Sequencing in the Diagnosis of Epilepsy and/or Intellectual Disability in a Pediatric Cohorte	COMPLETED
Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System)	Lupus	NA	NCT02892565	Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System)	COMPLETED

Publications

13

Molécule	Indication / population	Titre	Journal	Date
retrospective analysis of a panel result		Prevalence and genotypic distribution of human papillomavirus in India: Insights from a five-year retrospective laboratory-based study.	Diagnostic microbiology and infectious disease
retrospective analysis of a panel result		Diagnostic performance comparison of multiplex PCR-based BioFire® joint infection panel and conventional culture methods in septic arthritis: A single center, retrospective study.	Diagnostic microbiology and infectious disease
retrospective analysis of a panel result		Unbiased metabolomics screening for potential biomarkers in patients with In-stent restenosis post percutaneous coronary intervention.	Scandinavian cardiovascular journal : SCJ
PLASM-ALZ — Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers		Plasma p-tau217 measured by the Elecsys automated immunoassay: Prospective validation in a heterogeneous memory clinic cohort.	Journal of Alzheimer's disease : JAD
retrospective analysis of a panel result		Sex-related molecular phenotypes in anxiety-depressive disorders: a machine learning analysis of routine blood biomarkers.	Frontiers in psychiatry
retrospective analysis of a panel result		Validation of SeptiCyte RAPID to Discriminate Sepsis From Noninfectious Systemic Inflammation in Critically Ill Children.	Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
PLASM-ALZ — Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers		Plasma p-tau217 detects Alzheimer's disease co-pathology in cerebral amyloid angiopathy: Comparison to CSF biomarkers in the ANGMAR cohort.	Alzheimer's & dementia : the journal of the Alzheimer's Association
retrospective analysis of a panel result		Non-invasive differentiation between aplastic anemia and myelodysplastic syndromes based on an 8-feature lightGBM model: A multicenter external validation study.	Current research in translational medicine
retrospective analysis of a panel result		The relationship of EBER, EGFR, p16, and E-cadherin expressions with epithelial-mesenchymal transition and tumor budding in laryngeal squamous cell carcinoma.	European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
PLASM-ALZ — Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers		Detecting amyloid-β pathology in subjective cognitive decline using plasma and CSF biomarkers.	EBioMedicine
PLASM-ALZ — Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers		Diagnostic performance of plasma p-Tau217, p-Tau181, and p-Tau231 across the Alzheimer's disease continuum: a network meta-analysis.	Frontiers in aging neuroscience
retrospective analysis of a panel result		Health system implementation of clinical decision support to optimize respiratory pathogen profile utilization.	Journal of clinical microbiology
retrospective analysis of a panel result		Scaling Up Tuberculosis Preventive Treatment in the Brazilian Amazon (2016-2024): a Programmatic Report on Multi-sector Integration in Surveillance, Health Services and Academia.	Revista da Sociedade Brasileira de Medicina Tropical